RDPAC released the 2017 report of Meet the Challenges of Diabetes with Drug Innovation
[November 9, 2017, Shanghai] During the 26th “World Diabetes Day” approaching, RDPAC released 2017 report Meet the Challenges of Diabetes with Drug Innovation in Shanghai. The report shows the severe diabetes current situation and prevention and control status of our country at present, and introduces innovation drugs and the effect and meaning of diabetes innovation management for improving patient’s life and reducing the burden.
Diabetes is a common chronic disease which may bring complications such as eye disease, cardiovascular disease, pregnancy complications, diabetic foot and mouth disease, kidney disease, nerve damage and so on. Nowadays the cure of diabetes has become a focus of global attention, and the International Diabetes Federation has made a short-term goal to make treatment and medicine available to more and more type 2 diabetic patient.
Diabetes treatment success rates are less than 50%, related fees of diabetes increase rapidly
China is the world's number one diabetes country, with the largest number of patients in the world, and its adult diabetes prevalence is higher than the world level. According to the report of IDF, in 2015, there are 109.6 million diabetes patients in our country and the number is predicted to rise to 150.7 million in 2040.
Diabetes and its complications bring great burden to patients and their family. In 2015, the total fees of diseases related to diabetes in China is $51 billion, of which 84.6% of the cost is used for the treatment of complications. According to the prediction of IDF, in 2040, the total fees of diseases related to diabetes in China will reach $72 billion.
“At present, there is still a large gap between China and many other countries in the field of diabetes treatment and control, only 36.5% of the patients was diagnosed, of which only 32.2% of patients are undergoing diabetes medication.” Prof. Shi Yongquan said, who is the director of endocrinology department, Shanghai Changzheng Hospital, member of Chinese medical association’s diabetes branch and deputy director of endocrine society of Shanghai medical association, “The treatment success rate for diabetes patients in China is only 49.2%. I hope that the government, NGO, enterprises and individuals should work together to promote the development of innovation treatment as well as improve patients’ quality of life, and accelerate the achievement of the goal of China's prevention and cure of diabetes.”
178 kinds of diabetes drugs are under research to assistant China to deal with the challenge of diabetes
Type 2 diabetes is a kind of progressive disease, many drugs have effect on the control of blood sugar of patient initially, but as time goes on, they may lose effect. Therefore, new drugs or replacement therapy are needed to control the blood sugar. When this circumstance occurs, the access that patient gets other drugs is of great importance. If diabetes is well controlled, the complications will be less and the disease burden of patients and society will be also less. Now, there are over 178 kinds of innovative diabetes drugs under research.
Dr. Zhang Kezhou, the vice president of Clinical & Medical & Regulatory Novo Nordisk Greater China, said, “If diabetes patients can control the disease, we will see fewer complications, which will lower the burden on patients and their families. With an innovation-driven development strategy to tackle this problem in China, we are seeing innovative drugs that can effectively reduce in-hospital time and need for surgery, delay the development of complications and improve patients’ quality of life.”
The clinical research director of MSD China R&D Center, Tu Yingmei said, “In order to deal with the challenge of diabetes, new diabetes drugs are fast emerging, of which the research and development choose different point to overcome diabetes. Some new drugs, in addition to the hypoglycemic, improved the clinical outcomes, at the same time new diabetes drugs have gained more and more data of the cardiovascular safety. The pathogenesis of diabetes is complicated, so we need to work together, and strive to provide more safe and effective diabetes drugs for patients.”
“How to better help diabetic patients control their conditions is the great challenge China is facing. We need to, by in-depth understanding of patients’ diagnosis and treatment paths, better understand their real needs and facing difficulties, and maximize the treatment value that high quality innovative drugs and solutions bring to patients.” The head of Diabetes Business Unit of Sanofi China, Patrick Nowlin said, “In addition, we need to joint doctors, nurses and patients to set up an integrated system of disease education and tracking; and establish an overall solution that meets the practical needs of patients at each stage of their treatment.”
In January of this year, the General Office of the State Council issued Chinese Long-term Planning for Chronic Disease Prevention and Control (2017-2025), deploying to strengthen our country's chronic disease prevention and control work. The diabetes is key field of our country's long-term chronic disease prevention and control work. Its main goal is that by 2025, for people aged 30 to 70, the premature mortality caused by cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases and diabetes will reduce by 20% compared with that in 2015. Gradually improve the residents' health and life expectancy and effectively control the chronic disease burden. “Our goal is to innovate more safe, effective and personalized treatment options for patient.” Eric BOUTEILLER, Chairman of RDPAC, said: “We will work together with member companies to help China achieve its goal of medium and long-term planning for the fight against chronic diseases. At the same time, we also look forward to working together so that more patients will benefit from innovative drugs as soon as possible to better control the disease and enjoy life. “